15 brokerages give DexCom a "Moderate Buy" rating, with an average 12-month target price of $140.33.
DexCom, Inc. (NASDAQ:DXCM) has received a consensus "Moderate Buy" rating from 15 brokerages covering the firm, with an average 12-month target price of $140.33. Three analysts rated it as a hold, eleven as a buy, and one as a strong buy. Recent reports include Citigroup raising their price objective from $148.00 to $161.00 and UBS Group increasing their target from $153.00 to $163.00, both giving "buy" ratings.
June 28, 2024
3 Articles